CHeT Innovation

The CHeT Innovation is applying new tools and approaches in clinical trials to transform design, assessment, and evaluation of novel therapies for neurological disorders.

Over the past decade, CHeT Director Dr. Ray Dorsey has led more than 15 studies that utilize novel technologies to expand the reach and impact of research and clinical care worldwide.

CHeT has conducted a dozen virtual (“siteless”) studies using videoconferencing software to reach more than 1,500 participants throughout the country.

CHeT has pioneered studies of smartphones, wearables, and invisible sensors in collaboration with Apple, Biogen, MIT, Sage Bionetworks, and others.